Ardelyx 3Q 2026: Revenue $127.7M, Net loss $737K — 10-Q Summary

What happened

Ardelyx reported third-quarter 2026 revenue of $127.7 million, up 15.7% from $110.3 million a year earlier, and a net loss of $737,000, narrower than the prior-year loss of $969,000. Nine-month product sales rose 28% to $337.0 million, led by IBSRELA and XPHOZAH.

Confirmed

Global impact / market context

Higher product sales can support Ardelyx’s revenue, while increased rebates and other deductions on government managed-care sales mean less of each dollar billed may reach the company. The smaller quarterly loss is an improvement, but the report still shows a net loss.

Analyst inference

The report combines growth in product sales with pressure from gross-to-net adjustments, which are rebates and other deductions from sales. For investors, the key tension is whether demand growth can outweigh these deductions and move the company toward sustained profitability.

Analyst inference

What to watch

1. Track future revenue and product-sales reports to see whether IBSRELA and XPHOZAH continue growing and whether that growth translates into stronger financial results. Analyst inference
2. Watch for updates on government managed-care sales and rebates, since a higher share of sales absorbed by deductions could limit revenue reaching Ardelyx. Analyst inference
3. The company says ACCEL enrollment is complete and expects topline results in the second half of 2027; those results will provide evidence about tenapanor’s trial outcome. Confirmed

Evidence

• Original source link unavailable